BioRegenx, Inc.
BRGX
$0.008
$0.000.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -540.39% | -182.47% | -1,001.02% | -- | -- |
| Total Depreciation and Amortization | 46,135.42% | -- | 89,491.67% | -- | -- |
| Total Amortization of Deferred Charges | -- | 466.10% | 320.34% | -- | -- |
| Total Other Non-Cash Items | 696.69% | 13.06% | 139,733.33% | -- | -- |
| Change in Net Operating Assets | 225.85% | -76.18% | -84.12% | -- | -- |
| Cash from Operations | 78.60% | -151.35% | -159.14% | -- | -- |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Investing | 5.77% | -3,445.45% | -3,445.45% | -- | -- |
| Total Debt Issued | 564.36% | 131.47% | 130.98% | -- | -- |
| Total Debt Repaid | 77.18% | 71.33% | 63.87% | -- | -- |
| Issuance of Common Stock | -- | -35.33% | -21.48% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -63.29% | 197.55% | 193.60% | -- | -- |
| Foreign Exchange rate Adjustments | -84.57% | -110.15% | -96.95% | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 86.37% | -88.94% | -160.69% | -- | -- |